Trial Profile

An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab emtansine (Primary) ; Atezolizumab; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
Indications Advanced breast cancer; Male breast cancer
Focus Adverse reactions
Acronyms T-DM1 study
Sponsors Chugai Pharmaceutical; Genentech; Roche

02 Jan 2025 Planned End Date changed from 20 Sep 2029 to 30 Sep 2029.
02 Jan 2025 Planned primary completion date changed from 20 Sep 2029 to 30 Sep 2029.
12 Jul 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com